NEW YORK, March 12 – Three Bruker companies, Bruker Daltonics, Bruker AXS, and Bruker Instruments have agreed to work with Integrative Proteomics (IPI) to develop a high-throughput platform for protein identification and characterization, the companies said Monday.
IPI, based in Toronto, will purchase x-ray crystallography, high-field NMR, and MALDI-TOF mass spectrometry systems from Bruker. In addition, the Bruker companies will make an undisclosed equity contribution in IPI.
The companies also plan to develop a joint R&D effort to investigate new x-ray, NMR, and mass spectrometry techniques, specifically software, automation, and detection technologies for use in structural proteomics.
"Integrative Proteomics impressed us with their vision and leadership in the era of drug discovery based on the structure and function of pharmaceutical targets,” Frank Laukien, CEO of Bruker Daltonics, and chairman of Bruker AXS, said in a statement. "We will also make a strategic equity investment because we believe that IPI will capture significant value from the vast commercial potential of structural genomics for drug discovery."IPI’s proteomics platform consists of three systems: the Proteoworks platform for parallel production of recombinant proteins; the ProteoActive platform for investigating protein-protein interactions using mass spectroscopy; and the ProteoVision platform for determining protein structure with the help of NMR and x-ray crystallography.